Daré Bioscience (NasdaqCM:DARE) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker1Welcome to the conference call hosted by Daré Bioscience to review the company's third quarter 2025 financial results and to provide a business update. This call is being recorded. My name is Jericho, and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.Speak ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of I ...

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene Phase 3 Study Supports Continued Enrollment Exhibit 99.1 Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal Contraception Four Commercially Available Solutions for Women Expected Over the Next Tw ...

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probi ...

Event to Explore What Makes DARE to PLAY™ a First-of-Its-Kind Topical Sildenafil Cream for Women, Review Supporting Clinical Data, and Discuss 503B Pathway to Commercial Availability, Expected Before Year-EndSAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced it will host a live webinar on Monday, November 17, 2025, on ...

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (t ...

The project underscores Daré Bioscience’s growing role in shaping the future of contraceptive innovationSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabiliti ...

Core Insights - Daré Bioscience has entered into an agreement with the Gates Foundation to receive up to approximately $499,000 for mentorship and project management support for research projects addressing preeclampsia, a significant unmet need in maternal care [1][2][3] Company Overview - Daré Bioscience is a biopharmaceutical company focused on women's health, aiming to bridge the gap between scientific innovation and practical solutions [1][5] - The company seeks to bring innovative, evidence-based solutions to market that address long-standing unmet needs in women's health, including areas such as contraception, sexual health, and menopause [5] Engagement Details - The engagement with the Gates Foundation will involve providing strategic mentorship and technical guidance to organizations conducting preclinical research on preeclampsia prevention, diagnosis, and treatment [2][3] - Preeclampsia is a leading cause of maternal and infant morbidity and mortality, with approximately 76,000 mothers and 500,000 babies dying from the condition each year [3][4] Strategic Alignment - This initiative aligns with Daré's long-term strategy to lead in women's health areas that have significant needs and limited treatment options [4][5] - The multi-year engagement aims to enhance the impact and sustainability of research funded through the Gates Foundation's Grand Challenges initiative [3][4]

Company Performance - Dare Bioscience, Inc. reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of +18.18% [1] - The company has surpassed consensus EPS estimates for the last four quarters, but it reported revenues of -$0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 103.68% [2] - The stock has lost approximately 32.4% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $0.59 million, and for the current fiscal year, it is -$1.99 on revenues of $1.67 million [7] - The estimate revisions trend for Dare Bioscience was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - The company ended the quarter with approximately $5 million in cash and cash equivalents and a working capital deficit of approximately $12.6 million [17] - General and administrative expenses were $2.4 million compared to $2.5 million in 2024, primarily due to decreases in personnel costs and stock-based compensation [18] - Research and development expenses were $1.4 million, a 71% decrease versus Q2 2024, mainly due to reductions in R&D expenses recognized from non-dilutive funding awards [18] Business Line Data and Key Metrics Changes - The company is on track to support the commercial availability of DARE2PLAY Sildenafil Cream through a 503B outsourcing facility in Q4 2025, representing a significant milestone in women's sexual health [5][6] - Ovaprene, a hormone-free contraceptive candidate, continues to progress with the Phase three trial, receiving a recommendation to continue from the Independent Data and Safety Monitoring Board [10] - DARE HRT1, an intravaginal ring for hormone therapy, is pursuing both FDA approval and a 503B compounding opportunity, targeting availability in late 2026 [12][13] Market Data and Key Metrics Changes - The company is addressing a significant unmet need in the contraceptive landscape with Ovaprene, which could transform the market for hormone-free birth control [11] - The compounded hormone therapy market is estimated at $4.5 billion, where DARE HRT1 is expected to generate meaningful revenue [12] Company Strategy and Development Direction - The company is executing a dual path strategy, focusing on commercializing proprietary formulations while pursuing FDA approval for innovative women's health solutions [2][5] - The strategy includes leveraging non-dilutive capital and a disciplined investment approach to unlock value efficiently [6] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significant interest and unmet need in supporting women with arousal concerns, as evidenced by the feedback from the direct-to-patient awareness campaign [7] - The company remains optimistic about the potential of DARE2PLAY Sildenafil Cream as a near-term revenue driver and is excited about the ongoing clinical programs addressing women's health needs [9][15] Other Important Information - The company received approximately $17.6 million in net proceeds from sales of common stock and a $6 million grant payment after the quarter end, strengthening its balance sheet [17] - The company is preparing to launch two non-prescription vaginal probiotics designed to support vaginal microbiome health, complementing its prescription offerings [13] Summary of Q&A Session - Due to technical difficulties, there was no Q&A session held during the call [18]